<DOC>
	<DOC>NCT02967757</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.</brief_summary>
	<brief_title>In-market Utilisation of Liraglutide Used for Weight Management in Europe</brief_title>
	<detailed_description />
	<mesh_term>Nutrition Disorders</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Initiation of liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg (initiation is defined as no prescription of the same brand within the previous 12 months) Informed consent obtained before any studyrelated activities. Studyrelated activities are any procedures that are carried out as part of the study, including activities to determine suitability of the study Patients or physicians who previously participated in interventional studies for liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg will not be eligible to participate in the study For the full study, sites and patients included in the pilot will be excluded</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>